Show simple item record

dc.contributor.authorGamertsfelder, Elise
dc.contributor.authorDelgado Figueroa, Netzahualpilli
dc.contributor.authorKeestra, Sarai
dc.contributor.authorSilva, Alan Rossi
dc.contributor.authorBorana, Ronak
dc.contributor.authorSiebert, Maximilian
dc.contributor.authorBrückner, Till Daniel
dc.date.accessioned2024-01-16T11:59:15Z
dc.date.available2024-01-16T11:59:15Z
dc.date.issued2023-11-06
dc.description.abstractObjective - To assess to what extent the clinical trial policies of the largest public and philanthropic funders of clinical research in the United States meet WHO best practices in trial registration and reporting.<p> <p>Methods - Public and philanthropic funders of clinical trials in the USA with >US$50 million annual spend were selected. The funders were assessed using an 11-item scoring tool based on WHO Joint Statement benchmarks. These 11 items fell into 4 categories, namely: trial registration, academic publication, monitoring and sanctions. An additional item captured whether and how funders referred to Consolidated Standards of Reporting Trials (CONSORT) within their trial policies. Each funder was independently assessed by two or three researchers. Funders were contacted to flag possible errors and omissions. Ambiguous or difficult-to-score items were settled by an independent adjudicator.<p> <p>Results - Fourteen funders were assessed. Our cross-sectional study found that, on average, funders have only implemented 4.1/11 (37%) of WHO best practices in clinical trial transparency. The most frequently adopted requirement was open access publishing (14/14 funders). The least frequently adopted were (1) requiring trial ID to appear in all publications (2/14 funders, 14%) and (2) making compliance reports public (2/14 funders, 14%). Public funders, on average, adopted more policy elements (5.2/11 items, 47%) than philanthropic funders (2.8/11 items, 25%). Only one funder’s policy documents mentioned the CONSORT statement.<p> <p>Conclusions - There is a significant variation between the number of best practice policy items adopted by medical research funders in the USA. Many funders fell significantly short of WHO Joint Statement benchmarks. Each funder could benefit from policy revision and strengthening.en_US
dc.identifier.citationGamertsfelder, Delgado Figueroa, Keestra, Silva, Borana, Siebert, Brückner TD. Towards transparency: Adoption of WHO best practices in clinical trial registration and reporting among top medical research funders in the USA. BMJ Evidence-Based Medicine. 2023en_US
dc.identifier.cristinIDFRIDAID 2207512
dc.identifier.doi10.1136/bmjebm-2023-112395
dc.identifier.issn2515-446X
dc.identifier.issn2515-4478
dc.identifier.urihttps://hdl.handle.net/10037/32512
dc.language.isoengen_US
dc.publisherBMJ Publishing Groupen_US
dc.relation.journalBMJ Evidence-Based Medicine
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2023 The Author(s)en_US
dc.titleTowards transparency: Adoption of WHO best practices in clinical trial registration and reporting among top medical research funders in the USAen_US
dc.type.versionacceptedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record